Yes, Ozempic is a GLP-1 receptor agonist. Its active ingredient, semaglutide, is structurally 94% identical to the GLP-1 hormone your body produces naturally. The FDA has approved Ozempic specifically for managing type 2 diabetes, though the same molecule is sold under different brand names for other uses.
What GLP-1 Actually Does in Your Body
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does three things that matter for blood sugar control: it signals your pancreas to produce more insulin, it tells your liver to stop releasing stored sugar into your bloodstream, and it slows how quickly food leaves your stomach. That last effect is also why people on GLP-1 medications feel full longer after meals.
The problem is that natural GLP-1 breaks down in minutes. Your body has an enzyme that chews it up almost immediately. GLP-1 receptor agonists like Ozempic are engineered versions of this hormone that resist that breakdown, so the effects last days instead of minutes. Ozempic, specifically, is injected once a week.
How Ozempic Fits Into the GLP-1 Drug Class
Ozempic is one of several GLP-1 receptor agonists on the market. Others include dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta and Bydureon BCise), and tirzepatide (Mounjaro), which targets both GLP-1 and a second gut hormone receptor. Each works through the same basic mechanism but differs in dosing schedule, potency, and approved uses.
What makes Ozempic distinct is its active ingredient, semaglutide, and its approved indications. The FDA has cleared Ozempic for type 2 diabetes management, reducing cardiovascular risk in adults with type 2 diabetes and heart disease, and improving kidney health in adults with type 2 diabetes and chronic kidney disease. In clinical trials from the SUSTAIN program, the higher dose of Ozempic lowered A1c by up to about 1 percentage point more than comparator treatments, a significant improvement for diabetes management.
Ozempic, Wegovy, and Rybelsus: Same Drug, Different Names
This is where it gets confusing. Semaglutide is sold under three brand names: Ozempic (a weekly injection for diabetes), Wegovy (a weekly injection for weight management), and Rybelsus (a daily pill for diabetes). The molecule is identical across all three.
The key differences are dosage and what the FDA allows each to be prescribed for. Ozempic tops out at 2 mg per week, while Wegovy goes up to 2.4 mg per week as an injection and 25 mg as a pill. Wegovy is approved for weight management in adults and children 12 and older, for a type of fatty liver disease called MASH, and for cardiovascular risk reduction in adults with obesity or overweight who also have heart disease. Ozempic is not FDA-approved for weight loss, even though many people experience weight loss while taking it for diabetes.
What Taking Ozempic Feels Like
The most common side effects are gastrointestinal. Among thousands of reported cases in an FDA safety database analysis, nausea was the most frequent complaint, followed by vomiting, diarrhea, constipation, and abdominal pain. These effects tend to be worst in the early weeks, especially when your dose is being gradually increased, and often improve over time as your body adjusts.
The nausea and fullness are partly a feature, not just a bug. Slowed gastric emptying is one of the mechanisms that helps control blood sugar spikes after meals and contributes to reduced appetite. But for some people, these effects are intense enough to require a slower dose increase or, occasionally, switching to a different medication.
Why People Confuse GLP-1 With Ozempic
Ozempic has become so widely discussed that its name is often used as shorthand for the entire GLP-1 drug class, similar to how people say “Band-Aid” when they mean adhesive bandage. But GLP-1 is the hormone class, GLP-1 receptor agonist is the drug category, semaglutide is the specific molecule, and Ozempic is one brand name for that molecule at certain doses for certain conditions. Understanding the distinction matters if you’re comparing treatment options, because not all GLP-1 drugs are interchangeable in terms of potency, dosing frequency, or what they’re approved to treat.